OncoHost

02/18/2026

We are proud to announce the publication of our latest study in the Journal of Pharmaceutical and Biomedical Analysis (JPBA):
“Bridging the Gap: A Systematic Approach to Integrating Serum and Plasma Proteomic Datasets for Biomarker Studies.”

Our newly published work introduces a validated computational framework that harmonizes serum and plasma proteomic data, enabling systematic transformation between specimen types.
Importantly, we validated this bridging methodology using our AI-powered PROphet® platform. When applied to scaled serum data, the model maintained predictive accuracy, preserving clinical benefit classification and survival stratification in .

This milestone expands analytical flexibility, unlocks previously siloed datasets, and supports scalable multi-cohort validation - critical capabilities as proteomics becomes increasingly central to precision oncology.

We are grateful to our collaborators at the National Cancer Institute (NCI), Yale School of Medicine , Heidelberg University Hospital , and ions.bio for their partnership in advancing the field.

Read the news release here: https://tinyurl.com/ks3ww6hb
Read the full study here: https://doi.org/10.1016/j.jpba.2026.117421

/PRNewswire/ -- OncoHost, a technology company transforming precision oncology through proteomics and AI, today announced the publication of a new study in the...

02/17/2026

Industry News: FDA January 2026 - Key Highlights

January brought strong regulatory momentum in mutation-driven NSCLC:

🔬 Sevabertinib received Breakthrough Therapy Designation for 1L HER2-mutant NSCLC — expanding targeted options for a historically underserved subset.

🧬 Zoldonrasib earned Breakthrough status in KRAS G12D–mutant NSCLC post–PD-1/PD-L1 and platinum therapy — another step forward in cracking the RAS code.

🧪 Gotistobart secured Orphan Drug Designation for squamous NSCLC, signaling continued focus on high-unmet-need populations.

Precision isn’t the future — it’s the standard taking shape now.

Read more here: https://bit.ly/4c3rMYh

January 2026 marks a pivotal month in oncology, with the FDA advancing numerous innovative therapies for challenging cancers, emphasizing precision medicine.

02/16/2026

📄🧬PROphet is being recognized in a peer-reviewed biomarker landscape for metastatic !

A recently published review in Lung Cancer: Targets and Therapy highlights blood-based predictors of immune checkpoint inhibitor (ICI) response - and specifically calls out PROphet as a multi-analyte platform with clinical planning value.

Read the full review here: https://bit.ly/4pUlddQ

This link will take you to a page that’s not on LinkedIn

02/13/2026

February is National Cancer Prevention Month, a time to raise awareness about the steps we can all take to reduce cancer risk and prioritize our health.

Early detection and prevention are crucial in the fight against cancer. This month, let’s empower ourselves and our loved ones with the information and resources needed to make informed decisions about our health.

At OncoHost, we are committed to transforming cancer care through personalized treatment insights and cutting-edge research. Together, we can create a future with better outcomes and improved quality of life for cancer patients.

02/11/2026

🌍🔬 Celebrating Women & Girls in Science! 👩‍🔬💡

Today, on International Day of Women and Girls in Science, we honor the brilliant minds driving innovation in oncology and beyond. From groundbreaking research to transformative patient care, women continue to push the boundaries of cancer care and shape the future of medicine every day.

At OncoHost, we are incredibly proud of the talented women on our team who are making a profound impact in precision oncology. Your dedication, expertise, and passion are driving advancements in cancer research and helping improve patient outcomes worldwide.

02/10/2026

Every patient deserves a tailored approach—because in the fight against cancer, time is everything.

With OncoHost's cutting-edge PROphet® technology, we deliver actionable insights before treatment begins, helping clinicians make the best possible decisions from day one.

Because starting right makes all the difference.
Read more about PROphet® here: https://bit.ly/4cgNODS

Explore OncoHost's PROphet Technology, a cutting-edge precision oncology platform driving advancements in biomarkers for cancer treatment decisions.

02/05/2026

We are proud to see our CEO, Dr. Ofer Sharon, featured throughout the 2026 AI in Biologics Discovery report by Labiotech.eu , produced in partnership with ENPICOM.

This year’s report delivers a sharp look at the realities shaping AI adoption in biologics - not just the promise, but the operational and cultural shifts required to make it work.

Ofer’s perspective is woven throughout the analysis, emphasizing a truth the industry is rapidly converging on: AI impact depends less on algorithms alone — and more on data foundations, infrastructure readiness, and cross-disciplinary alignment.

🔍 The report explores:
• Adoption barriers — from fragmented data ecosystems to the “black box” trust gap
• How leading organizations are overcoming them — through standardized data environments, interoperable platforms, and human-AI collaboration models
• What’s next — democratization of AI tools, emerging regulatory standards, and new biologics innovation models powered by scalable AI integration

As highlighted in the report, AI will not replace scientists — it will amplify scientific intuition, enabling teams to see biological signals that were previously invisible. That’s the inflection point.

A big thank you to Alexander Burik and the Labiotech team for the seamless collaboration and thoughtful coverage of this evolving space.

The future of biologics discovery won’t be driven by AI alone — but by organizations that know how to operationalize it.

Read/download the report here: https://bit.ly/4rpraQQ

@

02/04/2026

Today we stand with the global community in recognizing World Cancer Day — a day dedicated to raising awareness, encouraging prevention, and mobilizing action in response to the worldwide impact of cancer.

This moment is a reminder that progress in oncology is driven by collective effort. Patients and families facing uncertainty. Clinicians making complex care decisions. Researchers expanding scientific understanding. Innovators translating insight into practical tools.

Advancing cancer care requires more than awareness — it demands alignment across prevention, early detection, research, and clinical decision-making. Each step forward strengthens our ability to support better-informed treatment strategies and improved patient outcomes.

Today, we acknowledge the global scale of the challenge — and the shared responsibility to keep moving science, medicine, and care forward.

02/02/2026

Thank you MLO - Medical Laboratory Observer for featuring our recent win in the 2025 ! We’re honored to be recognized for our efforts and remain dedicated to driving progress in precision oncology.

Read the full article here: https://bit.ly/46eblo2

OncoHost has been honored with the 2026 BIG Innovation Award in the Health category and named a Top 10 Small Business Innovator for its PROphet platform, an AI-powered plasma-...

01/29/2026

🧬PROphet is being recognized in a peer-reviewed biomarker landscape for metastatic !

In the review, PROphet is benchmarked in the top-tier evidence bracket across modalities with a score of 14 - the highest among proteomic & genomic predictors of poor ICI response in NSCLC reviewed.
Score 14 reflects the highest rating of consistency, statistical validity, relevant endpoint, confounder adjustment, external validation, large cohort, and data availability.

📄Scan the QR code below ro read the full report.

01/27/2026

When “more” isn’t better, biology matters.

New real-world evidence challenges a long-standing assumption in PD-L1 ≥50% NSCLC: that high tumor burden justifies upfront chemo-IO.

A new study shows that despite expert opinion referenced in American Society of Clinical Oncology (ASCO) guidelines, adding chemotherapy to pembrolizumab did not improve survival—even in patients with aggressive disease features—and came with significantly higher toxicity and hospitalizations.

Key takeaways:
• High tumor burden and large baseline lesions did not predict benefit from chemo-IO
• “Debulking” with chemotherapy did not enhance IO outcomes in PD-L1 ≥50% disease
• Clinical features alone failed to identify who truly benefits from treatment escalation

This isn’t about telling clinicians what to do. It’s about recognizing that exceptional cases shouldn’t become default practice - and that escalation decisions deserve more than surface-level clinical proxies.

As more commonly cited biomarkers fall short, the signal is clear:
👉 Clinical features are not enough. Biology matters.

That’s exactly where biology-based, host-response insights can add value - helping identify upfront who can do well on IO alone, and who may truly need intensification.

📄 Read the study: https://journals.sagepub.com/doi/10.1177/17588359251396266

Background: Pembrolizumab plus chemotherapy (Pembrolizumab-CT) has been suggested as first-line treatment over pembrolizumab alone in aggressive non-small-cell ...

01/25/2026

OncoHost is on the ground in Miami 🌴

Our Chief Commercial Officer and Director of Scientific Affairs are attending the Annual Winter Lung Cancer Conference in Miami Beach, engaging with the lung cancer community on the clinical and scientific questions shaping next-generation care.

From first-line decision-making to the evolving role of host-response biology, this meeting is where real-world insights meet real clinical needs. We’re here to listen, exchange perspectives, and continue advancing smarter, biology-driven precision oncology.